| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 169,506 | 169,394 | ||
| Marketable securities | 14,947 | 48,651 | ||
| Prepaid expenses and other current assets | 3,712 | 3,085 | ||
| Total current assets | 188,165 | 221,130 | ||
| Property and equipment, net | 9,303 | 9,521 | ||
| Right-of-use assets | 59,438 | 61,097 | ||
| Restricted cash | 5,031 | 5,031 | ||
| Long-term deposit and other assets | 288 | 1,782 | ||
| Total assets | 262,225 | 298,561 | ||
| Accounts payable | 6,353 | 4,539 | ||
| Accrued expenses and other current liabilities | 10,765 | 12,797 | ||
| Operating lease liability, current portion | 6,904 | 6,288 | ||
| Deferred revenue, current portion | 5,186 | 7,698 | ||
| Total current liabilities | 29,208 | 31,322 | ||
| Operating lease liability, net of current portion | 56,304 | 58,116 | ||
| Long-term debt and accrued interest | 32,414 | 32,296 | ||
| Other long term liabilities | 278 | 113 | ||
| Total liabilities | 118,204 | 121,847 | ||
| Common stock-Voting Common Stock | 5 | 5 | ||
| Common stock-Nonvoting Common Stock | 1 | 1 | ||
| Additional paid-in capital | 625,898 | 622,887 | ||
| Accumulated other comprehensive loss | 2 | -4 | ||
| Accumulated deficit | -481,885 | -446,175 | ||
| Total stockholders' equity | 144,021 | 176,714 | ||
| Total liabilities and stockholders' equity | 262,225 | 298,561 | ||
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)